Original InvestigationEffect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial
Section snippets
Study Design and Participants
This was a pilot, double-blind, parallel-group randomized clinical trial comparing daily CoQ10 antioxidant therapy at 2 different doses (600 and 1,200 mg/d) with matching placebo. Study participants were recruited by study coordinators from outpatient dialysis facilities in the Seattle metropolitan area from September 2011 through April 2013. Criteria for study participation included the following: patients receiving thrice-weekly maintenance HD for at least 90 days, age older than 18 and
Participant Characteristics
Overall, participants had a mean age of 54 ± 13 (standard deviation) years; 22 (34%) were women, 17 (26%) were black, and 25 (40%) had diabetes (Table 1). More than 90% of participants dialyzed using an arteriovenous fistula. Patients assigned to receive 600 mg of CoQ10 daily were younger, more likely to be black, and less likely to have diabetes compared with patients assigned to the placebo group. Patients assigned to receive 1,200 mg of CoQ10 daily were less likely to be black and more likely to
Discussion
In this randomized, double-blind, placebo-controlled study of maintenance HD patients, daily CoQ10 as antioxidant therapy was safe and well tolerated and resulted in a significant and dose-dependent increase in plasma CoQ10 levels compared to placebo. In addition, CoQ10 supplementation using a 1,200-mg daily dose significantly decreased plasma concentrations of F2-isoprostanes, a robust plasma marker of oxidative stress. In the primary intention-to-treat analysis, there was no significant
Acknowledgements
The authors acknowledge Bret A. Lynch, Jerry Gillick, RPh, and Deb Schaller, RPh, for assistance with formulating and compounding the placebo wafer.
Support: This work was supported by grants from the National Institutes of Health, including the National Center for Complementary and Alternative Medicine R21 AT004265 and R21 AT3844, National Institute of Diabetes and Digestive and Kidney Diseases T32 DK007467 and K24 DK62849, National Center for Advancing Translational Sciences KL2 TR000421 and
References (41)
- et al.
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
Kidney Int
(2000) - et al.
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia
Kidney Int
(2002) - et al.
Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients
Free Radic Biol Med
(2001) - et al.
The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial
JACC Heart Fail
(2014) - et al.
Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis
Am J Clin Nutr
(2013) - et al.
The effect of coenzyme Q10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus
Atherosclerosis
(2008) - et al.
Measurement of F2- isoprostanes and isofurans using gas chromatography–mass spectrometry
Free Radic Biol Med
(2013) - et al.
Role of hypoxia in the pathogenesis of renal disease
Kidney Int Suppl
(2005) - et al.
Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis
J Am Coll Cardiol
(2008) - et al.
Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens
Int J Cardiol
(2013)
Biomarkers of Oxidative Stress Study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?
Free Radic Biol Med
US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States
Am J Kidney Dis
Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study
J Am Soc Nephrol
Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy
Nephrol Dial Transplant
Oxidative stress and endothelial function in chronic renal failure
J Am Soc Nephrol
Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients
Clin Nephrol
Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
BMC Nephrol
Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension
Antioxid Redox Signal
Isoprostanes and isofurans as non-traditional risk factors for cardiovascular disease among Canadian Inuit
Free Radic Res
Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD
J Am Soc Nephrol
Cited by (52)
Stress system and related biomarkers in Parkinson's disease
2022, Advances in Clinical ChemistryCitation Excerpt :Moreover, salivary MDA has been recognized as an important stress biomarker in oral [134] and systemic diseases such as extra-pulmonary tuberculosis [135]. Some oxidative stress markers, i.e., F2-isoprostanes and isofurans in plasma, are related to excess cardiovascular risk and are very common in end-stage renal disease [136] and can predict poor respiratory outcomes and neuro-developmental risk in very preterm infants [137]. In addition, lipid oxidation could be a promising stress biomarker to diagnose systemic lupus erythematosus [138].
Antioxidant activity of coenzyme-Q; bright and dark side
2022, Antioxidants Effects in Health: The Bright and the Dark SideDelivery of coenzyme Q10 with mitochondria-targeted nanocarrier attenuates renal ischemia-reperfusion injury in mice
2021, Materials Science and Engineering CCitation Excerpt :Recent studies demonstrated that CoQ10 could reduce plasma lipoprotein and serum triglycerides levels in obesity and diabetes patients [30,31]. In addition, CoQ10 administration displayed promising anti-oxidative effects in diabetic rat model and patients [32]. Here, CoQ10 was encapsulated into the inner core of the mitochondria specific PEG-PCL-TPP nanoparticles (T-NPCoQ10), which could be delivered to the kidney epithelial cells efficiently (Fig. 3a and b).
In vivo AAV delivery of glutathione reductase gene attenuates anti-aging gene klotho deficiency-induced kidney damage
2020, Redox BiologyCitation Excerpt :Western blot confirmed that the 4-HNE level was significantly increased in kidneys of KL+/– mice relative to WT, which was notably diminished after GR gene transfer (Fig. 5B), indicating that in vivo expression of GR reduced renal lipid peroxidation damages due to Klotho deficiency. To confirm the anti-oxidative effect of AAV-GR in kidney, we monitored urinary 8-isoprostane concentration, another marker of renal oxidative stress [30–33], at different time points after AAV-GR delivery. A significantly higher urinary level of 8-isoprostane was found in KL+/– mice versus WT mice (Fig. 5C).
NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ<inf>10</inf>: A Randomized Double-Blind Trial
2020, Annals of Vascular SurgeryCitation Excerpt :In addition to the improved outcomes, CoQ10 supplementation reduces cardiac biomarkers that are identifiers of poor outcomes. In a small cohort of dialysis patients randomized to receive either daily CoQ10 (1,200 mg/day) versus placebo, plasma concentrations of the oxidant stress marker, F2-isoprostane, was reduced at 4 months.21 Of interest, in a prespecified group of patients, treatment lead to lower troponin-T and NT-Pro BNP levels as well, reinforcing an important link between oxidant stress and cardiac biomarkers.
Trial registration: www.ClinicalTrials.gov; study number: NCT01408680.